This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BTAI BioXcel Therapeutics (BTAI) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsInsider TradesNews and TrendsOwnership About BioXcel Therapeutics Stock (NASDAQ:BTAI) Get BioXcel Therapeutics alerts:Sign Up Key Stats Today's Range$0.07▼$0.0950-Day Range$0.07▼$1.1952-Week Range$0.07▼$4.29Volume42.29 million shsAverage Volume17.36 million shsMarket Capitalization$2.32 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingHold Company Overview BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for neuroscience and immuno-oncology indications. The company uses an artificial intelligence-driven drug development platform to identify and advance therapies by analyzing existing clinical and biomedical data, with the goal of improving the efficiency of drug discovery and development. BioXcel’s primary commercial product is IGALMI (dexmedetomidine) sublingual film, which the U.S. Food and Drug Administration approved in 2022 for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. The product is designed for administration under the tongue and is intended for use in a monitored healthcare setting. BioXcel Therapeutics is headquartered in New Haven, Connecticut, and has focused its clinical and commercial activities primarily on the U.S. market. The company was led by co-founder and Chief Executive Officer Vimal Mehta, who has overseen its efforts to develop AI-enabled therapies and expand the use of its neuroscience-focused product portfolio.AI Generated. May Contain Errors. Read More BioXcel Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks24th Percentile Overall ScoreBTAI MarketRank™: 1.206964262335 of 5 starsBioXcel Therapeutics scored higher than 24% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingBioXcel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialBioXcel Therapeutics has a consensus price target of $11.00, representing about 14,744.8% upside from its current price of $0.07.Amount of Analyst CoverageBioXcel Therapeutics has received no research coverage in the past 90 days.Read more about BioXcel Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioXcel Therapeutics are expected to grow in the coming year, from ($2.70) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioXcel Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioXcel Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about BioXcel Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BTAI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioXcel Therapeutics does not currently pay a dividend.Dividend GrowthBioXcel Therapeutics does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for BioXcel Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for BTAI on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, BioXcel Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders3.70% of the stock of BioXcel Therapeutics is held by insiders.Percentage Held by Institutions30.68% of the stock of BioXcel Therapeutics is held by institutions.Read more about BioXcel Therapeutics' insider trading history. Receive BTAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioXcel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BTAI Stock News HeadlinesBioXcel Therapeutics Transitions to BX Liquidation VehicleOctober 30 at 6:10 PM | tipranks.comBiotech Gainers: BTAI Asset Deal, BIAF CyPath Growth, CYPH Zcash, GRI Pipeline Drive GainsSeptember 3, 2026 | rttnews.comMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks. | Weiss Ratings (Ad)BioXcel Therapeutics, Inc.(NasdaqCM:BTAI) dropped from S&P TMI IndexSeptember 2, 2026 | marketscreener.comMBioXcel Therapeutics Enters Asset Sale Agreement With Teva Pharmaceuticals; Stock DownAugust 31, 2026 | rttnews.comBioXcel Therapeutics Initiates Chapter 11 and Sale ProcessAugust 30, 2026 | theglobeandmail.comBioXcel Therapeutics Agrees To Teva Asset SaleAugust 28, 2026 | rttnews.comBioXcel Therapeutics Amends Credit Agreement Amid Liquidity StrainAugust 28, 2026 | theglobeandmail.comSee More Headlines BTAI Stock Analysis - Frequently Asked Questions How were BioXcel Therapeutics' earnings last quarter? BioXcel Therapeutics, Inc. (NASDAQ:BTAI) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by $0.05. The business had revenue of $182 thousand for the quarter, compared to analysts' expectations of $485 thousand. When did BioXcel Therapeutics' stock split? Shares of BioXcel Therapeutics reverse split before market open on Monday, February 10th 2025.The 1-16 reverse split was announced on Thursday, February 6th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2025. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did BioXcel Therapeutics IPO? BioXcel Therapeutics (BTAI) raised $65 million in an initial public offering on Thursday, March 8th 2018. The company issued 5,454,545 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager. What other stocks do shareholders of BioXcel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioXcel Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Micron Technology (MU), Alibaba Group (BABA), NIO (NIO) and Moderna (MRNA). Company Calendar Last Earnings8/13/2026Today11/02/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 BTAI's financial health is in the Red zone, according to TradeSmith. BTAI has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BTAI CIK1720893 Webwww.bioxceltherapeutics.com Phone(475) 238-6837FaxN/AEmployees90Year Founded2017Price Target and Rating Average Price Target for BioXcel Therapeutics$11.00 High Price Target$17.00 Low Price Target$5.00 Potential Upside/Downside+14,744.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($3.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.90 million Net Margins-9,549.87% Pretax Margin-9,549.87% Return on EquityN/A Return on Assets-185.82% Debt Debt-to-Equity RatioN/A Current Ratio0.21 Quick Ratio0.21 Sales & Book Value Annual Sales$640 thousand Price / Sales3.63 Cash FlowN/A Price / Cash FlowN/A Book Value($4.37) per share Price / Book-0.02Miscellaneous Outstanding Shares31,310,000Free Float30,148,000Market Cap$2.32 million OptionableOptionable Beta0.19 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:BTAI) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersThe 401k Email 70 Million Investors Might DeleteAn email announcing a new 401k investment option is headed to roughly 70 million inboxes. Most recipients will...Brownstone Research | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | SponsoredDoes your nest egg have an expiration date?A $250,000 nest egg growing at 5% a year and paying out $2,500 a month runs dry in just over a decade. Start w...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTAI Stock Alerts